New Alzheimer’s drug shows promise in small trial
Treatment reduced brain plaques, but effects on mental function not clear
PLAQUE BUSTER In a trial of 165 people, brain scans showed reductions in amyloid-beta plaques (red) in people given the antibody aducanumab compared with a placebo. Higher doses caused more amyloid reduction.
J. Sevigny et al/Nature 2016